Gene · 623
Papers2,473
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
501 to 520 of 2,473
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| New Structural Perspectives in G Protein-Coupled Receptor-Mediated Src Family Kinase Activation. | Int J Mol Sci | 2021 | 34204297 | PubTator, text mining | PubMed |
| eNAMPT Is Localised to Areas of Cartilage Damage in Patients with Hip Osteoarthritis and Promotes Cartilage Catabolism and Inflammation. | Int J Mol Sci | 2021 | 34201564 | PubTator, text mining | PubMed |
| Do Changes in ACE-2 Expression Affect SARS-CoV-2 Virulence and Related Complications: A Closer Look into Membrane-Bound and Soluble Forms. | Int J Mol Sci | 2021 | 34201415 | PubTator, text mining | PubMed |
| Exploiting Knowledge on Structure-Activity Relationships for Designing Peptidomimetics of Endogenous Peptides. | Biomedicines | 2021 | 34200402 | PubTator, text mining | PubMed |
| In Vitro and In Silico Characterization of G-Protein Coupled Receptor (GPCR) Targets of Phlorofucofuroeckol-A and Dieckol. | Mar Drugs | 2021 | 34199834 | PubTator, text mining | PubMed |
| GPCRs: The most promiscuous druggable receptor of the mankind. | Saudi Pharm J | 2021 | 34194261 | PubTator, text mining | PubMed |
Heteromerization between α2A adrenoceptors and different polymorphic variants of the dopamine D4 receptor determines pharmacological and functional differences. Implications for impulsive-control disorders. | Pharmacol Res | 2021 | 34182128 | PubTator, text mining | PubMed |
| A Dual-Route Perspective of SARS-CoV-2 Infection: Lung- vs. Gut-specific Effects of ACE-2 Deficiency. | Front Pharmacol | 2021 | 34177593 | PubTator, text mining | PubMed |
| Micronutrient therapy and effective immune response: a promising approach for management of COVID-19. | Infection | 2021 | 34160789 | PubTator, text mining | PubMed |
| Potential biomarkers for the early prediction of SARS-COV-2 disease outcome. | Microb Pathog | 2021 | 34153419 | PubTator, text mining | PubMed |
| The Efficacy and Safety of Esmolol for Septic Shock: A Systematic Review and Meta-analysis of Randomized Controlled Trials. | Front Pharmacol | 2021 | 34140891 | PubTator, text mining | PubMed |
| β-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now? | Vasc Health Risk Manag | 2021 | 34135591 | PubTator, text mining | PubMed |
| Vasoactive Peptides: Role in COVID-19 Pathogenesis and Potential Use as Biomarkers and Therapeutic Targets. | Arch Med Res | 2021 | 34134920 | PubTator, text mining | PubMed |
| Transcriptional drug repositioning and cheminformatics approach for differentiation therapy of leukaemia cells. | Sci Rep | 2021 | 34131166 | PubTator, text mining | PubMed |
| Effect of Landiolol Hydrochloride on Hemodynamics in a Histamine-Induced Shock Model. | Drugs R D | 2021 | 34128200 | PubTator, text mining | PubMed |
| A Comparative Review of the Extrinsic and Intrinsic Factors Regulating Lactose Synthesis. | J Mammary Gland Biol Neoplasia | 2021 | 34125363 | PubTator, text mining | PubMed |
| The contact system in liver injury. | Semin Immunopathol | 2021 | 34125270 | PubTator, text mining | PubMed |
| Case report of Takotsubo syndrome following seizures in a patient with pyruvate carboxylase deficiency. | Eur Heart J Case Rep | 2021 | 34109288 | PubTator, text mining | PubMed |
| Gene Cascade Shift and Pathway Enrichment in Rat Kidney Induced by Acarbose Through Comparative Analysis. | Front Bioeng Biotechnol | 2021 | 34095098 | PubTator, text mining | PubMed |
| The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications. | Inflamm Res | 2021 | 34086061 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/623/papers?page=26